Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Gastrointestinal Cancers

27 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    Colon
    Rectal

    VICCGI15122

    01/15/2016

    Research Use of Human Biospecimens from Colorectal Cancer Patients (Pilot Study)

    Basic Science

    VICCGI0283

    06/01/2002

    Novel Gastrointestinal Cancer Markers in Tissue and Biofluids

    Diagnostic

    Liver

    VICCGI14124

    03/13/2015

    PET Imaging of Hepatocellular Carcinoma with 18F-FSPG

    Other

    Liver

    VICCGI1523

    07/01/2015

    Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Registry

    Other

    Colon
    Rectum

    VICCGI99003

    08/01/2010

    Personalized Prevention of Colorectal Cancer

    Other

    Colon
    Rectal

    VICCGI0721

    01/09/2007

    Vanderbilt Hereditary Colorectal Cancer Registry

    Prevention

    Colon

    GIS0820-M

    07/09/2013

    A double blind placebo controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colon ca in patients with stage 0-III colon ca; phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac

    Treatment

    Gastric/Gastroesophageal
    Liver
    Lung

    VICCPHI15114

    09/28/2016

    An Open-Label, Multicenter, Phase 1 study of Ramucirumab plus MEDI4736 in Patients with Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

    Treatment

    Breast
    Lung
    Non Small Cell
    Ovarian
    Pancreatic

    VICCPHI1671

    08/02/2016

    A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

    Treatment

    Pancreatic

    ECOGGIEA2131

    07/28/2016

    A Phase I and Randomized, Double-Blinded Phase II Study of nab-Paclitaxel/Gemcitabine plus AZD1775 or Placebo in Treatment-Naive Metastatic Adenocarcinoma of the Pancreas

    Treatment

    Bladder
    Colon
    Gastric/Gastroesophageal
    Kidney (Renal Cell)
    Rectal
    Urologic

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    Colon
    Head/Neck
    Liver
    Lung
    Miscellaneous
    Neuro-Oncology
    Rectal
    Sarcoma
    Thyroid

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Treatment

    Colon
    Rectal

    VICCGI1623

    03/16/2016

    A Randomized, Controlled, Parallel, Multicenter Study Assessing Perfusion Outcomes with PINPOINT? Near Infrared Fluorescence Imaging in Low Anterior Resection

    Treatment

    Colon
    Head/Neck
    Lung
    Lymphoma
    Melanoma
    Non Small Cell
    Ovarian
    Rectal

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    Gastric/Gastroesophageal

    VICCGI1515

    01/05/2016

    A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

    Treatment

    Bladder
    Breast
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Gynecologic
    Head/Neck
    Kidney (Renal Cell)
    Lung
    Melanoma
    Non Small Cell
    Pancreatic
    Rectal
    Urologic
    Uterine

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    Pancreatic

    ECOGGIS1505

    11/17/2015

    A Randomized Phase II Study of Perioperative Mfolfirinox versus Gemcitabine/NAB-PACLITAXEL as Therapy for Resectable Pancreatic Adenocarcinoma

    Treatment

    Colon
    Esophageal
    Gastric/Gastroesophageal
    Liver
    Pancreatic
    Rectal

    VICCGIP1536

    10/26/2015

    A Phase 1 Study of Alisertib (MLN8237) in combination with mFOLFOX in Gastrointestinal Tumors

    Treatment

    Bladder
    Breast
    Hematologic
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myelodysplastic Syndrome
    Pancreatic
    Urologic

    VICCHEMP1558

    10/09/2015

    A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    Liver

    VICCGI1586

    07/31/2015

    A Humanitarian Device Exemption Treatment Protocol of TheraSphere? for Treatment of Primary Liver Cancer

    Treatment

    Breast
    Lung
    Pancreatic

    VICCPHI1528

    07/22/2015

    A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors

    Treatment

    Pancreatic

    VICCGI1507

    06/16/2015

    NAB-PACLITAXEL (ABRAXANE) plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC): An International, Open-Label, Multi-Center, Phase 2 Study (LAPACT)

    Treatment

    Bladder
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Neuro-Oncology
    Ovarian
    Urologic
    Uterine

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

    Treatment

    Pancreatic

    VICCGI1370

    12/30/2013

    A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

    Treatment

    Neuroendocrine
    Pancreatic

    VICCGI1250

    04/09/2013

    A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

    Treatment

    Liver

    CTSUGI80702-M

    05/05/2011

    A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with Resected Stage III Colon Cancer

    Treatment

    Liver

    CTSUGIC80802-M

    12/07/2010

    Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)


    Print this page for your doctor